Opioid antagonist naloxone considered safe for over-the-counter use
The US FDA have approved the distribution of naloxone, a drug that reverses opioid overdose, in an over-the-counter setting, in some dosage forms.
The opioid crisis was declared a public health emergency in the US in 2017. Since then, pharmaceutical companies have been working on solutions to ease the epidemic.
In some states across the US opioid overdose is the leading cause of death in adults ages 18–44 years.
Naloxone, an opioid antagonist, is used to reverse opioid overdose. It works by attaching to opioid receptors and blocking other opioids, reversing the effects.
It can be administered as a nasal spray or injected into the muscle, skin or veins, and is effective in reversing opioid overdoses in all dosage forms.
The US FDA have now confirmed that naloxone is safe and effective for over-the-counter use, in certain approved forms of administration.
The regulations cover a dose of up to 4 mg of a naloxone nasal spray and a dose of 2 mg via an auto injector, after initial assessments.
The FDA is still gathering data on individual products from various manufacturers to establish whether they can also be available for over-the-counter use. They have yet to see whether these products, which supply the drug in different forms, will be considered safe in this setting, as well as examining higher dosage forms.
Currently, doctors can prescribe naloxone as a life-saving antidote to opioid overdose, if administered quickly to patients prescribed high-dose opioids. Some states in the US allow the use of the drug without prescription, or through official community programmes.
In 2020, over 16,000 people died from overdoses involving just prescription opioids, this figure has increased year on year.
By making the opioid antagonist more accessible to at-risk patients, the number of deaths due to overdose will hopefully start to decrease.
Related News
-
News How to disrupt an industry as big as pharma for the better?
In this interview, hear from Matthew Wise, Head of Data at CCD Partners, on the companies they've been looking into that are offering new and interesting perspectives that have the potential to shake up the pharmaceutical industry, and how they'... -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa. -
News Latest updates for semaglutide: reduction of renal failure risk
Recent data presented at the 2024 European Society for Cardiology (ESC) conference analysed Novo Nordisk’s Ozempic (semaglutide) and its effectiveness in the management of chronic kidney disease (CKD). This follows previous analysis on semaglutid... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance